ITEM 5 – OTHER INFORMATION
−Removed: During the quarter ended March 31, 2024, no director
+Added: During the quarter ended June 30, 2024, no director
or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in
4 unchanged sentences
EXHIBIT NUMBER
−Removed: Certification of Jeffrey F.
−Removed: Eisenberg, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Confidential Separation Agreement and General Release, dated June 19, 2024, between Jeffrey Eisenberg and Xenetic Biosciences, Inc.
+Added: Confidential Separation Agreement and General Release, dated June 19, 2024, between Curtis Lockshin and Xenetic Biosciences, Inc.
+Added: Amendment to Employment Agreement, dated June 18, 2024, between James F.
+Added: Parslow and Xenetic Biosciences, Inc.
+Added: Certification of James Parslow, Interim Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certifications of Jeffrey F.
−Removed: Eisenberg, Principal Executive Officer, and James Parslow, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in inline XBRL, include:
−Removed: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
−Removed: Cover Page Interactive Data File (formatted in XBRL and included in Exhibit 101).
+Added: Certification of James Parslow, Interim Principal Executive Officer and Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in inline XBRL, include:
+Added: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
+Added: Cover Page Interactive Data File (formatted in inline XBRL and included in Exhibit 101)
Filed herewith.
4 unchanged sentences
Xenetic Biosciences, Inc.
−Removed: /s/ JEFFREY F.
−Removed: Chief Executive Officer
−Removed: (Principal Executive Officer)
+Added: August 13, 2024
/S/ JAMES PARSLOW
James Parslow
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer and Principal Accounting Officer)
+Added: Interim Chief Executive Officer and Chief Financial Officer
+Added: (Principal Executive, Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.